Nariman K Badr El-Din

Prof. Dr. Nariman K Badr El-Din


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2010 in European Journal of Cancer
Verified
Journal Article
Open access
PDF file
NMNadia M. Mokhtar
Nadia M. Mokhtar
AEAbdelbaset A. El-Aaser
Abdelbaset A. El-Aaser
MEMohamed N. El-Bolkainy
Mohamed N. El-Bolkainy
HIHamdy A. Ibrahim
Hamdy A. Ibrahim
NENariman K Badr El-Din
Nariman K Badr El-Din
NMNagia Z. Moharram
Nagia Z. Moharram
The Authors would like to draw your attention to the fact that the middle initial of the fifth author was omitted in their original publication. This author’s name is Nariman K. Badr El-Din as correctly stated above.

Verified
Journal Article
Open access
PDF file
ZEZeinab Elmotwaly
Zeinab Elmotwaly
MGMamdooh Ghoneum
Mamdooh Ghoneum
MEMai Alaa El-Dein
Mai Alaa El-Dein
SMSarah Yahia Moustafa
Sarah Yahia Moustafa
IEIbrahim M. El-Sherbiny
Ibrahim M. El-Sherbiny
NENariman K Badr El-Din
Nariman K Badr El-Din
MGN-3 (Biobran), a denatured hemicellulose compound derived from rice bran, possesses potent immunomodulatory and antitumor activity; however, its clinical application is constrained by non-specific tissue distribution, rapid systemic elimination, and poor cellular uptake. To overcome these pharmacological limitations, we engineered MGN-3-loaded lipid nanoparticles (MGN-3.LNPs) formulated with bioactive cinnamon and avocado oils to optimize targeted drug delivery against solid carcinoma. Mice bearing subcutaneous Ehrlich Ascites Carcinoma (EAC) solid tumors received free MGN-3, plain lipid nanoparticles (plain LNPs), or MGN-3.LNPs three times weekly from day 8 to day 26 post-inoculation. The administration of MGN-3.LNPs achieved superior tumor volume suppression (95.00%) compared to free MGN-3 (69.00%) and plain LNPs (63.00%) (p < 0.0001). Mechanistically, MGN-3.LNPs effectively inhibited cancer cell proliferation by suppressing Ki-67 expression while promoting expression shifts that strongly suggest the engagement of mitochondrial-mediated apoptotic signaling, including upregulation of tumor protein p53, Caspase-3, Caspase-9, poly(ADP-ribose) polymerase (PARP), and cytosolic cytochrome c (Cyt c), alongside an elevated Bax/Bcl-2 ratio and reduced 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels. Flow cytometric analysis confirmed that MGN-3.LNPs induced marked G0/G1 cell cycle arrest and promoted sub-G1 apoptotic cell accumulation, which was corroborated by Annexin V/propidium iodide (Annexin V/PI) staining and semiquantitative histopathological evaluation. Furthermore, MGN-3.LNPs downregulated the gene expression of proinflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) while restoring redox homeostasis in tumor tissues. Overall, lipidic nanoencapsulation significantly enhances the therapeutic efficacy of MGN-3 against solid tumors through superior nanoscale tissue penetration, prolonged retention, and synergistic lipid–drug bioactivity.